390815-66-4

Basic information

• Product Name: 3-Pyridinecarboxylic acid, 5-amino-6-(cyclohexylamino)-, ethyl ester
• CAS NO: 390815-66-4
• Molecular Formula: C14H21N3O2
• Molecular Weight: 263.34
• Mol File: 390815-66-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 3-Pyridinecarboxylic acid, 5-amino-6-(cyclohexylamino)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxylic acid, 5-amino-6-(cyclohexylamino)-, ethyl ester(390815-66-4)
• EPA Substance Registry System: 3-Pyridinecarboxylic acid, 5-amino-6-(cyclohexylamino)-, ethyl ester(390815-66-4)

Safety Data

• Hazardous Substances Data: 390815-66-4(Hazardous Substances Data)

Upstream product

• 7477-10-3 6-chloro-5-nitronicotinic acid 
• 171876-22-5 SRS₁₄-84 
• 108-91-8 cyclohexylamine 
• 390815-67-5 SRS₁₄-85 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS

The present disclosure provides, inter alia, a compound having the structure (1). Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods f

MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS

The present invention provides, inter alia, a compound having the structure of Formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS

The present invention provides, inter alia, a compound having the structure: (Formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.